Clovis Oncology, Inc. provided revenue guidance for the fourth quarter and full year of 2020. On January 11, 2021, the Company announced preliminary estimated unaudited global product revenues for Rubraca in the range of $43.0 million to $43.5 million for the quarter ended December 31, 2020 (which included estimated U.S. product revenues in the range of $36.3 million to $36.7 million and estimated ex-U.S. product revenues in the range of $6.5 million to $6.8 million for such quarter). The company announced also preliminary estimated unaudited global product revenues for Rubraca in the range of $164.2 million to $164.7 million for the year ended December 31, 2020.